Single User License
INR 101895
Site License
INR 203790
Corporate User License
INR 305685

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Santen Pharmaceutical Co., Ltd.-Product Pipeline Review-2015

Santen Pharmaceutical Co., Ltd.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Santen Pharmaceutical Co., Ltd.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Santen Pharmaceutical Co., Ltd.-Product Pipeline Review-2015', provides an overview of the Santen Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Santen Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Santen Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Santen Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Santen Pharmaceutical Co., Ltd.'s pipeline products

Reasons To Buy

Evaluate Santen Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Santen Pharmaceutical Co., Ltd. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Santen Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Santen Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Santen Pharmaceutical Co., Ltd.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Santen Pharmaceutical Co., Ltd. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Santen Pharmaceutical Co., Ltd. Snapshot 6

Santen Pharmaceutical Co., Ltd. Overview 6

Key Information 6

Key Facts 6

Santen Pharmaceutical Co., Ltd.-Research and Development Overview 7

Key Therapeutic Areas 7

Santen Pharmaceutical Co., Ltd.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Combination Treatment Modalities 12

Pipeline Products-Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Santen Pharmaceutical Co., Ltd.-Pipeline Products Glance 15

Santen Pharmaceutical Co., Ltd.-Late Stage Pipeline Products 15

Pre-Registration Products/Combination Treatment Modalities 15

Filing rejected/Withdrawn Products/Combination Treatment Modalities 16

Phase III Products/Combination Treatment Modalities 17

Santen Pharmaceutical Co., Ltd.-Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

Santen Pharmaceutical Co., Ltd.-Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Santen Pharmaceutical Co., Ltd.-Drug Profiles 21

(tafluprost + timolol maleate) 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

diquafosol tetrasodium 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

sirolimus 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

tafluprost 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

levofloxacin 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

cyclosporine 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

DE-117 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

DE-120 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

latanoprost 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

lomerizine 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

dexamethasone dipropionate 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

SA-14867 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

TRC-105 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Santen Pharmaceutical Co., Ltd.-Pipeline Analysis 41

Santen Pharmaceutical Co., Ltd.-Pipeline Products by Target 41

Santen Pharmaceutical Co., Ltd.-Pipeline Products by Route of Administration 43

Santen Pharmaceutical Co., Ltd.-Pipeline Products by Molecule Type 44

Santen Pharmaceutical Co., Ltd.-Pipeline Products by Mechanism of Action 45

Santen Pharmaceutical Co., Ltd.-Recent Pipeline Updates 47

Santen Pharmaceutical Co., Ltd.-Dormant Projects 52

Santen Pharmaceutical Co., Ltd.-Dormant Projects 52

Santen Pharmaceutical Co., Ltd.-Discontinued Pipeline Products 53

Discontinued Pipeline Product Profiles 53

DE-102 53

DE-104 53

DE-105 53

evodenoson 53

gefarnate 53

olmesartan 54

ONO-6126 54

rivoglitazone 54

Santen Pharmaceutical Co., Ltd.-Company Statement 55

Santen Pharmaceutical Co., Ltd.-Locations And Subsidiaries 59

Head Office 59

Other Locations & Subsidiaries 59

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64

List of Tables

Santen Pharmaceutical Co., Ltd., Key Information 6

Santen Pharmaceutical Co., Ltd., Key Facts 6

Santen Pharmaceutical Co., Ltd.-Pipeline by Indication, 2015 9

Santen Pharmaceutical Co., Ltd.-Pipeline by Stage of Development, 2015 10

Santen Pharmaceutical Co., Ltd.-Monotherapy Products in Pipeline, 2015 11

Santen Pharmaceutical Co., Ltd.-Combination Treatment Modalities in Pipeline, 2015 12

Santen Pharmaceutical Co., Ltd.-Partnered Products in Pipeline, 2015 13

Santen Pharmaceutical Co., Ltd.-Partnered Products/ Combination Treatment Modalities, 2015 14

Santen Pharmaceutical Co., Ltd.-Pre-Registration, 2015 15

Santen Pharmaceutical Co., Ltd.-Filing rejected/Withdrawn, 2015 16

Santen Pharmaceutical Co., Ltd.-Phase III, 2015 17

Santen Pharmaceutical Co., Ltd.-Phase II, 2015 18

Santen Pharmaceutical Co., Ltd.-Phase I, 2015 19

Santen Pharmaceutical Co., Ltd.-Preclinical, 2015 20

Santen Pharmaceutical Co., Ltd.-Pipeline by Target, 2015 42

Santen Pharmaceutical Co., Ltd.-Pipeline by Route of Administration, 2015 43

Santen Pharmaceutical Co., Ltd.-Pipeline by Molecule Type, 2015 44

Santen Pharmaceutical Co., Ltd.-Pipeline Products by Mechanism of Action, 2015 46

Santen Pharmaceutical Co., Ltd.-Recent Pipeline Updates, 2015 47

Santen Pharmaceutical Co., Ltd.-Dormant Developmental Projects,2015 52

Santen Pharmaceutical Co., Ltd.-Discontinued Pipeline Products, 2015 53

Santen Pharmaceutical Co., Ltd., Other Locations 59

Santen Pharmaceutical Co., Ltd., Subsidiaries 60

List of Figures

Santen Pharmaceutical Co., Ltd.-Pipeline by Top 10 Indication, 2015 8

Santen Pharmaceutical Co., Ltd.-Pipeline by Stage of Development, 2015 10

Santen Pharmaceutical Co., Ltd.-Monotherapy Products in Pipeline, 2015 11

Santen Pharmaceutical Co., Ltd.-Partnered Products in Pipeline, 2015 13

Santen Pharmaceutical Co., Ltd.-Pipeline by Top 10 Target, 2015 41

Santen Pharmaceutical Co., Ltd.-Pipeline by Top 10 Route of Administration, 2015 43

Santen Pharmaceutical Co., Ltd.-Pipeline by Top 10 Molecule Type, 2015 44

Santen Pharmaceutical Co., Ltd.-Pipeline Products by Top 10 Mechanism of Action, 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Santen Pharmaceutical Co., Ltd.; Santen Pharmaceutical Co., Ltd. - Key Therapeutics; Santen Pharmaceutical Co., Ltd. - Pipeline Overview and Promising Molecules; Santen Pharmaceutical Co., Ltd. - News; Santen Pharmaceutical Co., Ltd. - Latest Updates; Santen Pharmaceutical Co., Ltd. - Pipeline; Santen Pharmaceutical Co., Ltd. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com